美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Lazertinib Mesylate	Tablet	II (Paddle)	75	1.0% Polysorbate 20 in 0.1 M Sodium Citrate Buffer (80 mg strength), pH 4.5; 2.0% Polysorbate 20 in 0.1 M Sodium Citrate Buffer, pH 4.5 (240 mg strength)	900	5, 10, 15, 20, 30, 45 and 60	2026/01/28
Ledipasvir/Sofosbuvir	Tablet	II (Paddle)	75	1.5% Polysorbate 80 in 10 mM Potassium Phosphate Buffer with 0.0075 mg/mL Butylated Hydroxytoluene (BHT), pH 6.0	900	5, 10, 15, 20, 30, 45 and 60	2015/08/27
Ledipasvir/Sofosbuvir	Pellets	II (Paddle)	75	1.0% polysorbate 80 in 25 mM Potassium Phosphate Buffer, with 0.005 mg/mL Butylated Hydroxytoluene (BHT), pH 5.5	900	5, 10, 15, 20, 30, 45 and 60	2021/08/19
Lefamulin Acetate	Tablet	II (Paddle)	50	0.1 N HCl	1000	10, 20, 30, 45, 60, 75, and 90	2021/04/22
Leflunomide	Tablet			Develop a dissolution method			2023/09/15
Leflunomide (100 mg)	Tablet			Develop a dissolution method			2023/09/15
Lemborexant	Tablet	II (Paddle)	50	0.1 N HCl	900	5, 10, 15, 20 and 30	2022/05/12
Lenacapavir Sodium	Tablet	II (Paddle) with sinkers	75	30 mM potassium phosphate, pH 6.0 with 2.0% Cremophor EL	900	10, 15, 20, 25, 30, 45 and 60	2024/02/05
Lenalidomide	Capsule	II (Paddle)	50	0.01 N HCl	900	10, 15, 20, 30 and 45	2008/04/15
Leniolisib Phosphate	Tablet	I (Basket)	100	Acetate Buffer, pH 4.0	900	10, 20, 30, 40, 50, 60, 70 and 80	2024/08/05
Lenvatinib Mesylate	Capsule	II (Paddle)	50	0.1 N HCl	900	5, 10, 15, 20 and 30	2016/03/17
Lesinurad	Tablet	II (Paddle)	75	pH 4.5 sodium acetate buffer with 1% SLS	900	10, 20, 30 and 45	2016/03/17
Letermovir	Tablet	II (Paddle)	75	25 mM Na Acetate Buffer, pH 4.5 with 0.6% Tween-80	900	10, 15, 20, 30, 45 and 60	2018/02/08
Letermovir	Pellets	II (Paddle)	75	25 mM sodium acetate buffer, pH 4.5 with 0.6% Tween-80	900	5, 10, 15, 20, 30, 45 and 60	2026/03/25
Letrozole	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Letrozole (LET); Ribociclib Succinate (RIB)	Tablet/Tablet (Copackage)	II (Paddle)	RIB: 50; LET: 75	RIB: 0.01 N HCl; LET: 0.1 N HCl	RIB: 900; LET: 900	5, 10, 15, 20, 30 and 45	2019/03/07
Leucovorin Calcium	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Leuprolide Acetate	Implant			Develop a method to characterize in vitro releas			2022/05/12
Leuprolide Acetate	Injectable (Extended Release)			Develop a dissolution method using USP IV (Flow-Through Cell), and, if applicable, Apparatus II (Paddle) or any other appropriate method, for comparative evaluation by the Agency			2010/01/15
Leuprolide Mesylate	Emulsion			Develop a method to characterize in vitro release			2023/10/06